Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for SCI
Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Spinal Cord Injury
The Foundation for Orthopaedics and Regenerative Medicine
15 participants
Dec 1, 2024
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of intrathecal injection of cultured autologous adult adipose derived mesenchymal stem cells versus cultured allogeneic adult umbilical-cord derived mesenchymal stem cells for the treatment of spinal cord injury
Eligibility
Inclusion Criteria2
- Diagnosis of Spinal Cord Injury
- Understanding and willingness to sign a written informed consent document
Exclusion Criteria11
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Anticoagulation medicine use
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
- Previous organ transplant
- Hypersensitivity to sulfur
- Continued drug abuse
- Pre-menopausal women not using contraception
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
cultured autologous adult adipose derived mesenchymal stem cells
Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal injection for
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05018793